ClinicalThought

Share

Program Content

Activities

  • NSCLC: A Look Ahead
    Immunotherapy and Targeted Therapy in NSCLC: Where Are We Going in 2018?
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 28, 2017

  • Managing <i>ALK</i>+ NSCLC
    My Approach for Managing Patients With Progressive ALK-Positive NSCLC
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 22, 2018

  • New Nivolumab Dosing
    A New Nivolumab Dosing Option for Our Patients With Advanced NSCLC
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 16, 2018

  • Lung Cancer at AACR 2018
    First-line Therapy in NSCLC: What You Need to Know From AACR 2018
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2018

  • Progression After New ICI Options
    New Immunotherapy Paradigms Earlier in NSCLC: What Comes After Progression?
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 26, 2018

  • <i>ALK</i>+ NSCLC: Brigatinib
    My Thoughts on First-line Treatment for ALK-Positive NSCLC Today
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: October 24, 2018

Provided by

ProCE Banner

Supporters

AstraZeneca

Bristol Myers Squibb

Celgene TEXT Only

Genentech TEXT Only

Lilly

Merck Oncology

Novartis Pharmaceuticals Corporation

Takeda Oncology